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Summary
A monoclonal antibody (mAb) directed against a synthetic peptide derived from the sequence
of the humanimmunodeficiency virustype 1(HIV1) regulatory protein virion infectivity factor
(vif) labeled the surface of Schistosoma mansoni schistosomula by indirect immunofluorescence .
Western blotting showed that two S. mansoni proteins of 170 and 65 kD were recognized by
the mAb. Sera from 20% ofS. mansoni-infected HIVseronegative individuals tested recognized
the PS4 peptide in an ELISA as did sera from S. mansoni-infected rats. Sera from individuals
seropositive for HIV-1, but without schistosomiasis, that reacted with the vifpeptide also recognized
a 170-kD S. mansoni protein . This crossreactive S. mansoni antigen appears to be a target ofimmunity
in vivo since passive transfer of the mAb VIF-CD3 to naive rats had a protective effect against
a challenge infection with S. mansoni cercariae.
O
ne of the main characteristics ofHIV infection in Africa
is that it principally affects populations in areas of
chronic parasitic infections . This has raised the possibility of
a mutual influence on the development of the respective dis-
eases in the case of concomitant infections. In this context,
seroepidemiological studies suggested a relationship between
HIV-1 and both malaria and schistosome infections (1, 2) .
In schistosomiasis, it was shown that patients had a high
proportion of antibodies against HIV-1 and that there was
no antigenic crossreactivity between Schistosoma mansoni and
HIV-1 structural proteins (3) . While investigating a possible
crossreactivity between HIV-1 proteins and S. mansoni an-
tigens, we confirmed the absence of crossreactivity between
HIV-1 structural virion proteins (gag, pol, env) and S. man-
soni. However, we demonstrate an immunological crossreac-
tivity between an epitope of virion infectivity factor (vif) one
of the six nonstructural regulatory proteins encoded by the
HIV-1 genome, and an S. mansoni surface antigen .
Materials and Methods
Parasites andAntigen Preparations .
￿
A Puerto Rican strain of S.
mansoni was maintained in Biomphalaria glabrata snails and golden
hamsters . Schistosomula were prepared by skin penetration (4) .
Adult worms were prepared by hepato-portal perfusion ofinfected
hamsters .
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Soluble extracts of adult worms and cercariae were produced
as previously described (5) . The complete coding sequence of the
LAV1 Bru isolate of the VIF protein was expressed in Escherichia
coli, as described elsewhere (r vif) (6), and purified to >60% for
use in Western blotting analysis .
Sera.
￿
IOU rats, percutaneously infected by 1,500 cercariae, were
the source ofinfected rat sera . Human infection sera were obtained
from children living in an endemic area in Kenya that has been
extensively reported (5, 7-8). These sera were seronegative for HIV-1
structural proteins (ELAVIA; Pasteur Diagnostic, Lille) .HIV-1 sera
were obtained from European individuals seropositive for struc-
tural proteins gag, pol, and env who had never been in contact
withS . mansoni . Normal human sera were obtained from individ-
uals negative for both infections .
Synthetic Peptides.
￿
The vif peptide comprising amino acids
155-168 was selected as a probable epitope after algorhythm anal-
ysis for criteria of hydrophilicity, helicity, mobility, and amphiphi-
licity, and was synthesized by solid-phase methodology (9, 10) .
The amino acid sequence of this peptide, named PS4, was TPKK
IKPPLPSVTK (11) . The composition ofthe peptide was confirmed
by amino acid analysis, and the degree of purity was assessed by
C-18 reversed-phase HPLC. Two other vif peptides were used
throughout the experiments : the vif 32-50 peptide named PS2 was
SGKARGWFVRHHVESPHPR; the vif 85-105 peptide named
PS3 wasVSIEWRKKRYSTQVDPELAD.A control peptide, PEI
(847-861), derived from the sequence of theHIV env protein (IPR
RIRBGLERILL), was used as a control .
RatmAbs.
￿
mAbs to the vifpeptide were obtained in a homol-
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traperitoneally with 100 ltg ofpurified vif peptide (PS4) conjugated
to tetanus toxoid in the presence ofCFA followed by two injec-
tions of 100 pg of peptide alone in IFA . One clone (VIF-CD3)
of theIgMisotype was selected for further investigations and used
for the production of ascitic fluids .
Ascitic fluids (1 ml) were injected intravenously into five LOU
rats in each group (10wk old), which had been infected with 1,200
S. mansoni cercariae 4 h previously. Parasite burdens were evaluated
3 wk later, as described previously (13) . Results were compared
by student's t test .
Western Blotting and Indirect Immunofluorescence.
￿
Electrophoresis
andWestern blotting ofproteins were as previously described (14) .
mAbs and human sera were used at a 1:100 dilution, and bound
antibody was detected with peroxidase-labeled mouse anti-rat IgM
(Serotec) or rabbit anti-human Ig (H+L ; Institut Pasteur Produc-
tion) . Surface binding ofmAB antibodies was detected by indirect
fluorescence on live or fixed schistosomula prepared as described
elsewhere (15) .
ELISA andInhibition Assay.
￿
Microtiter plates (Nuns, Roskilde,
Denmark) were coated with 100 ul of adult worm antigens at 10
14g/ml or peptides at 5 mg/ml. For inhibition experiments, the
mAb anti-vifpeptide was preincubated for 3 h at 37°C with pep-
tides at different concentrations. In all experiments, the antibodies
were incubated overnight at 4°C, and the wells were then washed
with PBS/0.4% Tween . The anti-Igs used were the same as de-
scribed above. Each test was assessed in duplicate . Results are ex-
pressed as mean ± SD.
Results and Discussion
Of the 550 hybrid cell supernatants screened using the
ELISA, four showed specific anti-vifpeptide (PS4) reactivity.
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Figure 2 .
￿
Localization of the antigenic sites recognized by the
mAb VIF-CD3 directed against PS4 vif peptide. Indirect fluorescence
was performed on fixed S . mansoni schistosomula incubated with the
mAb and developed with FITC anti-rat (H+L) . (top) mAb vif-CD3 ;
(bottom) control mAb IgM anti-O volvulus .
These antibodies were tested for their ability to react with
theE . coli-expressed recombinant vifprotein (Fig. 1 A), and
one clone namedvif-CD3 (IgM isotype) was retained for fur-
ther investigations . Ascitic fluids were produced andused to
probe Western blots of whole S . mansoni cercarial antigen,
revealing two bands at 170 and 65 kD (Fig. 1 B) . The 170-
Virion Infectivity Factor Epitope Crossreacts with S . mansoni Antigen
Figure 1 .
￿
Epitopic identity between the
HIV -1 vif protein and S . mansoni antigens.
(A) Immunoblot of vif protein (purified up
to 60%) with normal rat serum (NRS)
(a); sera from rats immunized with tetanus
toxoid (b); rat mAb IgM anti-Oncbocerca
volvulus (unrelated IgM) (c); rat IgM mAb
anti-vif peptide PS4 (VIF-CD3) (d) ; serum
from a rat immunized with the PS4 pep-
tide (e) . (B) Identification of S . mansoni
components recognized by the mAb VIF-
CD3 . Western blot was performed on cer-
carial antigens extracted in TNSTE. (Lanes
a-d) Normal rat serum; sera from rats in-
fected 8 wk previously with S . mansoni ;
unrelated rat mAb IgM ; and the IgM
mAb VIF-CD3 anti-PS4, respectively.kD band was also detected in adult worm products, along
with a weak band at 43 kD (data not shown) . The mAb
vif-CD3 in ascitic fluidsbound to the surface of live or fixed
schistosomula up to a dilution of 1:800 (Fig. 2) . A kinetic
study showed that only 10% of 3-h skin schistosomula gave
a weakmembrane fluorescence, whereas all schistosomula gave
a strong surface fluorescence after an 18-h incubation inMEM.
These results suggested that the expression of this epitope
at the surface may be developmentally regulated . Negative
controls used included an unrelated IgM class ratmAb (directed
against an Onchocerca volvulus antigen) that gave no fluores-
cence . An ELISA was used to further assess the specificity
ofbinding ofmAb vif-CD3 to S. mansoni antigens . The PS4
peptide inhibited (up to 60%) the binding of the mAb to
soluble adult worm antigens, whereas another peptide de-
rived from the vif sequence (PS3) showed no inhibition . When
the mAb was preincubated with intact schistosomula and then
tested for its ability to bind to peptide PS4, a significant (45%)
inhibition was obtained; confirming that the crossreactive an-
tigens were located at the surface of the larvae.
The possibility that the crossreactive epitope expressed at
the surface of schistosomula might be a target ofimmunity
was addressed by the passive transfer of 1 ml of mAb VIF-
CD3 to rats 4 h before infection with 1,200 cercariae . The
parasite burden was evaluated 3 wk later by liver perfusion
and showed a significant level of protection (p < 0.02) com-
pared with control groups injected with saline in four sepa-
rate experiments (46, 40, 34, and 49%) . In comparison, the
protection level that can be conferred by an anti-S. mansoni
mAb is -60% (12) . Passive transfer of an unrelated mAb
of the same isotype (IgM) did not confer any protection (two
of the four experiments) . These results suggest that the S.
mansoni epitope defined bymAbVIF-CD3 represents a poten-
tial target of effector mechanisms operating in vivo .
To determine the relevance of these observations to schis-
tosomiasis, we investigated whether crossreactive antibodies
were produced during the course of human and rat infec-
tions . A total of 61 sera from S. mansoni-infected individuals
that were all negative for HIV-1 structural proteins were tested
for their capacity to bind to the PS4 peptide in ELISA . 12
reacted significantly (data not shown), whereas no sera gave
a positive result with the PS2 vif peptide nor with the con-
trol env peptide (PE1) . None of the 18 sera from HIV-1-
negative and S. mansoni-negative Europeans recognized any
of the peptides. To rule out the possibility that latent HIV-1
infection (16) might be involved at the presence of anti-PS4
antibodies in the sera of the S. mansoni-infected patients, sera
from experimentally infected rats were also tested in the PS4
ELISA . Sera from three of six 6-8-wk infected rats reacted
significantly with PS4 when compared with normal rat sera,
but did not recognize the control peptides. Conversely, sera
from 11 European individuals seropositive forHIV-1 and with
no schistosomiasis were tested for the presence of antibodies
to both the PS4 vif peptide and to S. mansoni cercarial an-
tigens . 5 of 11 gave a positive PS4 ELISA, three others were
borderline. Of the positive or borderline cases, six recognized
the 170-kD S . mansoni antigen, and one ofthem recognized
an additional 62-kD antigen . Two of eight that recognized
PS4 did not recognize any specific S. mansoni band, suggesting
that the PS4 peptide might not represent the complete cross-
reactive epitope, or alternatively, that only a part of PS4 is
the crossreactive epitope .
It appears from these results that a proportion of individ-
uals infected either with HIV-1 or S. mansoni produce anti-
bodies to a common epitope that is at least partly defined
by the PS4 peptide and correspond to a S. mansoni 170-kD
surface antigen that appears to be a potential target of pro-
tective immunity. For this reason, we have purified the cross-
reactive antigen fraction in order to undertake its molecular
cloning and to define more exactly its relationship to the HIV-1
vif protein . No hybridization was obtained between vifcDNA
and S. mansoni genomicDNA, suggesting that the crossreac-
tivity may involve a very limited DNA sequence only ; or
amino acid peptide sequence homology that does not cor-
respond toDNA sequence, or alternatively, to a conforma-
tional epitope . Our results raise the question of the possible
influence of a prior humoral and cellular response to a cross-
reacting S. mansoni antigen on an HIV infection . We are at
present testing the possibility that anti-S. mansoni immune
mechanisms may exert an effect on HIV-1 replication or HIV-
1-infected cells .
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